Ozempic & GLP-1 Drug Side Effects
Were you or a loved one affected? Get a free case evaluation today.
Case Overview
GLP-1 receptor agonist medications including Ozempic, Wegovy, Mounjaro, and Rybelsus have been linked to severe gastrointestinal side effects beyond what was disclosed to patients and prescribers. Originally developed for diabetes management, these drugs have been widely prescribed for weight loss, but reports of serious adverse events have prompted investigations and lawsuits against manufacturers Novo Nordisk and Eli Lilly.
Health Risks & Injuries
- Gastroparesis (stomach paralysis)
- Severe nausea and vomiting
- Pancreatitis
- Bowel obstruction
- Gallbladder disease
- Thyroid cancer
- Kidney injury
- Intestinal blockage
Who Qualifies
- Patients who took Ozempic, Wegovy, Mounjaro, or Rybelsus
- Those who developed gastroparesis or severe GI issues while on GLP-1 drugs
- Patients hospitalized due to adverse reactions
- Those who developed pancreatitis, gallbladder problems, or bowel obstruction
Current Litigation Status
MDL established in the Eastern District of Pennsylvania. Hundreds of lawsuits filed with more being added regularly. Manufacturers Novo Nordisk and Eli Lilly are primary defendants. Bellwether case selections underway for 2026 trials.
Free Case Evaluation
Find out if you qualify for compensation. No fees unless we win your case.
Get Started Now(800) 555-1234
Get Help With Your Ozempic/GLP-1 Case
Our experienced attorneys are ready to evaluate your claim. Free consultation, no obligation.